

Our Reference: C19RM 2021 ADDITIONAL FUNDING - Zambia

Bishop Paul Mususu
Chairperson, Zambia Country Coordinating
Mechanism
c/o National HIV/AIDS, STI, TB Council
P.O Box 38718
Lusaka
Republic of Zambia

Geneva, 25 March 2021

Subject: 2021 COVID-19 Response Mechanism Additional Funding for Zambia

Dear Bishop Mususu,

Thank you for your commitment in the fight against the COVID-19 pandemic.

The Global Fund has reviewed your recent COVID-19 Response Mechanism (**C19RM**) Additional Fast-Track Funding Request and approved USD 15,412,951 of additional investments for Zambia's COVID-19 response (**C19RM Additional Award**). This brings your total C19RM award (including all C19RM awards received to date) to USD 112,078,332 (**C19RM Total Award**).

After careful review, we regret to inform you that the Global Fund is unable to approve:

- USD 210,671 in Human Resources costs including 10 oxygen attendants with the Ministry of Health and 3 lab positions with the Churches Health Association of Zambia.
- USD 90,725 in SAR-Cov 2 Genomic sequencing and Bioinformatics. This activity shall be funded through savings.
- USD 12,173 across various Health Products and non-Health Products lines, due to alignment of the budget to the final HPMT.

The Global Fund Country Team will provide the details on these points.

Please note that the C19RM Additional Award is additional to the Global Fund 2020-2022 allocation to the Republic of Zambia and any C19RM funding awarded to date. The C19RM Additional Award will become part of the grants (**Grants**) listed in the table below:

Grant	Amount Awarded (US\$)	Implementation Period dates
ZMB-C-CHAZ	USD 3,465,465	01/01/2021 to 31/12/2023 (inclusive)
ZMB-C-MOH	USD 11,947,486	01/01/2021 to 31/12/2023 (inclusive)

The C19RM Additional Award will cover the approved interventions and activities set out in the Additional Funding Request C19RM Budget (C19RM Budget) and the Additional C19RM Health Products Management Template (C19RM HPMT) enclosed with this letter. Further recommendations relating to the C19RM Additional Award are set out in Annex 1 to this letter.

While the deadline for use of the C19RM Additional Award is **31 December 2023**, recipients are expected to use these funds **as soon as possible** to address urgent needs and only for the purposes for which the funding was approved and pursuant to the terms and conditions of the corresponding grant agreements for the relevant Grant (**Grant Agreement**) and this letter. Specifically, the Principal Recipients are expected to place necessary procurement requisitions for approved health products (whether through PPM/wambo.org or approved local channels) as swiftly as possible. For Zambia, the Principal Recipients are expected to submit initial requisitions for PPM/wambo.org orders by no later **5 April 2022**.

The C19RM Additional Award must be incorporated into the Grants, by no later than **25 May 2022**. If the Implementation Letter is not signed by this date, the payment of any purchase requisitions raised under the Global Fund's Pooled Procurement Mechanism for approved health products will be deducted from the C19RM Additional Award and/or the products may be rerouted.

In the meantime, given the urgency of the nature of the activities for which the C19RM funds were awarded, the Principal Recipients may utilize any available uncommitted funds under the relevant Grant to initiate implementation of the approved C19RM activities that are detailed in the C19RM Budget and C19RM HPMT, in accordance with the terms and conditions of the relevant Grant Agreements and this letter. Unless otherwise agreed by the Global Fund in writing, by initiating implementation of the approved C19RM activities, the Principal Recipients are deemed to have accepted the terms and conditions of the relevant Grant Agreement and the conditions applicable to the Principal Recipients in this letter.

The Global Fund Country Team will be in touch with the Principal Recipients to discuss the process for initiating implementation of the approved C19RM activities.

We stand ready to support Zambia in responding to the COVID-19 pandemic, which threatens to destroy years of progress against HIV and TB. To defeat COVID-19, protect progress against HIV and TB, and save lives, we must unite to fight.

Yours sincerely



Mark Eldon-Edington
Division Head
Grant Management

Cc: Dr George Magwende, Permanent Secretary – Administration, Ministry of Health
Mrs. Karen Sichinga, Executive Director, Churches Health Association of Zambia
Mr. Chris Chikatula, Administrator, Zambia Country Coordinating Mechanism
Mrs. Charity Mulenga, Local Fund Agent, PricewaterhouseCoopers

encl: C19RM HPMT
C19RM Budget
C19RM Procurement Progress Reporting Template

Annex 1: Recommendations to use of the C19RM Additional Award¹

Legal Requirements to form part of the Grant Agreement

1. C19RM Health Products Reporting

- a. Each Principal Recipient shall adhere to the procurement channel arrangements approved in the enclosed C19RM HPMT for each relevant Grant Agreement, and shall not make any amendments to these arrangements without the prior written approval of the Global Fund.
- b. No later than the tenth (10th) day of each calendar month of the Implementation Period and the tenth (10th) day of the calendar month immediately after the Implementation Period end-date, each Principal Recipient shall complete and submit to the Global Fund's satisfaction, the C19RM Procurement Progress Reporting Template setting out the: (i) purchase order issue date; (ii) vendor-promised delivery date; (iii) date of product dispatch from the manufacturer; and (iv) date of product delivery for each:
 - i. C19RM Strategic Health Product and Mainstream Health Product procured outside of the Global Fund's Pooled Procurement Mechanism; and
 - ii. C19RM Local Sourcing Advised Products with Enhanced Reporting,as such terms are defined in the Global Fund C19RM Guidelines (as may be amended from time-to-time and notified to the Principal Recipient in writing)
- c. Each Principal Recipient shall take all appropriate and necessary actions to ensure that any relevant Sub-recipient, supplier, contractor or agent provides the Principal Recipient with such information as may be required for the Principal Recipient to comply with its obligations set out in paragraph 1 (b) above.

Other recommendations to be addressed during implementation

1. Each Principal Recipient agrees that the Global Fund may request the LFA to undertake a pre-award procurement review of health products and related support services (including technical support and warranty and maintenance services) procured through national sourcing channels under the C19RM Additional Award to ensure that the health products and services procured are value for money and also

¹ The applicant and Principal Recipient will note that some of these recommendations also apply to prior C19RM awards and will have been communicated to the applicant and Principal Recipient on 10 June 2021 and 30 July 2021

that the procurements will be conducted in accordance with Article 5 of the Global Fund Grant Regulations (2014).

2. The Global Fund may, through the LFA and/or any independent entity appointed by the Global Fund, conduct the reviews listed below which may inform further recommendations during implementation. Each Principal Recipient agrees to cooperate with and facilitate such reviews in accordance with Articles 7.6 and 4.4 of the Global Fund Grant Regulations (2014):
 - a. Reviews to monitor warehousing, distribution and usage of health products procured under the C19RM Additional Award (including pre-delivery reviews) to confirm supply chain arrangements and reviews of specific supply chains such as cold chain, and laboratory supply chain; and
 - b. Reviews to monitor operationalization (procurement, installation and appropriate use) of PSA oxygen generator plants and oxygen equipment (concentrators, ventilators) procured under the C19RM Additional Award.
3. During the implementation period, each genomic sequencing laboratory must achieve a passing score of 85% in SARS-Cov-2 genomic sequencing proficiency testing panel surveys that are coordinated by an approved external quality assessment (“EQA”) provider.
4. The implementation of Laboratory System interventions (USD 523,129) will be subject to receipt by the Global Fund of Full CCM endorsement prior to implementation, as they are not part of the approved Unfunded Demand.
5. Each Principal Recipient is expected to work with the Ministry of Health of the Republic of Zambia and the CCM to ensure periodic reporting on the country’s COVID-19 burden in accordance with World Health Organization guidance. These data are to be reported via Excel using the form “[Global Surveillance of COVID-19: WHO process for reporting aggregated data- V2](#)” or through the dedicated submission weekly surveillance platform (for further information please email covidsurveillance@who.int). The dataset should include age and gender of cases and deaths, and infections and deaths among health workers. Compliance with such reporting will be monitored by the Global Fund using the WHO COVID-19 surveillance dashboard on an ongoing basis to facilitate grant management and investment decisions.